CF PharmTech, Inc. filed a Next Day Disclosure Return showing that on 7 May 2026 it repurchased 10,500 H-shares on the Hong Kong Stock Exchange. The purchase price ranged from HKD 21.60 to HKD 21.86 per share, giving a volume-weighted average of HKD 21.71. Total consideration amounted to HKD 0.23 million.

Following the transaction, the number of issued shares (excluding treasury shares) fell from 301.55 million to 301.54 million, while treasury shares increased to 0.69 million. Total issued shares remained unchanged at 302.22 million.

The buy-back was executed under the repurchase mandate approved on 16 December 2025, which authorises the company to repurchase up to 30.22 million shares. To date, 0.69 million shares have been repurchased under this mandate, representing 0.23 % of the company’s issued share capital on the mandate date.

The board confirmed that the repurchase complied with all applicable Hong Kong Listing Rules and regulatory requirements. In accordance with HKEX Rule 10.06(3)(a), CF PharmTech is subject to a moratorium on issuing new shares or transferring treasury shares until 6 June 2026.